Branded generic medicines marketed to Indian doctors through field forces and sold through chemists - the core of the Indian pharmaceutical market (IPM).
Sun Pharmaceutical IndustriesOperator · HighListed
Mankind PharmaOperator · HighListed
Torrent PharmaceuticalsOperator · HighListed
Alkem LaboratoriesOperator · HighListed
Abbott IndiaOperator · HighListed
Eris LifesciencesOperator · HighListed
CiplaOperator · MediumListed
Zydus LifesciencesOperator · MediumListed
Ipca LaboratoriesOperator · MediumListed
Ajanta PharmaOperator · MediumListed
Intas PharmaceuticalsOperator · HighUnlisted
Intas Pharmaceuticals
Unlisted top-3 Indian drugmaker - India branded formulations plus Accord (Europe/US generics) and Accord BioPharma biosimilars
Strengths
Among the largest Indian companies by revenue, with leading European generics and oncology/biosimilar businesses
Risks
Unlisted - no public market data; past USFDA observations at its Ahmedabad plants
Background
Privately held (Ahmedabad); backed by Temasek
One of India's top-3 companies in the domestic market and a large exporter via Accord Healthcare
Compiled from public reporting — not exchange-listed.
Where it fits
Turns molecules into brands: companies in-license or make formulations, build them into doctor-recognised brands through large medical-representative (MR) field forces, and sell through ~65,000 stockists to India's chemists. In India almost every off-patent medicine is a 'branded generic', so brand and prescriber loyalty, not patents, decide market share.
Why it matters
This is the steadiest and highest-return profit pool in Indian pharma: no US-style price erosion, high gross margins (60-80%), modest capex and cash-rich balance sheets. It is also where the sector's best compounders (Sun's India business, Torrent, Abbott India, Mankind) live, and why consolidation deals in this layer command 30x+ EBITDA.
Where the value pool sits
Pharmarack puts the IPM at ~₹2.4L Cr for calendar 2025 (+8.1%), with August 2026 value growth of 10.7%. Growth is mostly price and new launches (annual WPI-linked hikes on NLEM drugs, freer pricing on non-scheduled brands); volume growth is near zero. Chronic therapies (cardiac, anti-diabetic, CNS, GI) grow faster and are stickier than acute ones (anti-infectives, respiratory), so chronic-heavy portfolios earn premium valuations.
Key drivers
Chronic disease burden (diabetes, hypertension, obesity) and rising insurance coverage
Patent expiries in India (sitagliptin 2022, empagliflozin 2025, semaglutide Mar 2026) creating large new branded-generic markets
Brand acquisitions from MNCs and smaller peers (Torrent-JB, Mankind-Bharat Serums, Eris-Biocon brands)
Annual WPI-linked price increases on scheduled drugs plus up to 10% a year on non-scheduled brands
Potential bottlenecks
Price control: ~15-18% of the market sits under NLEM/DPCO ceiling prices, and NPPA can cap trade margins or add drugs to the list
Field-force productivity - MR costs rise every year and incremental reps add less
Trade-generic and Jan Aushadhi channels pressure prices in commoditised molecules
Revised Schedule M (WHO-GMP aligned) raises compliance cost for smaller makers
Investor metrics to watch
IPM share and rank (Pharmarack / IQVIA)
Domestic growth vs IPM growth, split into price / volume / new launches